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1. INTRODUCTION
The primary objective of this market study was to provide
in-depth field findings relative to the market potential of
the Biological Isolation Garment (BIG). Discussion on the
following pages focuses on 1 f ,.o nature and size of the antici-
pated market, analysis of rl nical acceptability and commercial
potential and conclusions au.l recommendations.
2. BACKGROUND
;.L Product Description
The Biological Isolation Garr.ient was originally designed
for the Apollo Astronauts to wear upon return to earth to avoid
the possibility of their contaminating the environment.
	 The
concept was then adapted for medical use to protect certain
patients from env ironmental contamination and the risk of
infection. A prototype garment was developed and has been
tested in clinical u:^- by the National Cancer Institute with
favorable results.
The BIG consists of a coverall type suit with attached
mittens and slippers, all made with a penetration resistant
fabric, "BAR-BAC". The fabric prevents penetration of
particles of greater than 0.3 microns in diameter. A separate
hood with a transparent face mask is attached to the suit.
The entire garment is easily sterilized. Air is supplied
through a diffuser at the top of the head; a flexible tube
conducts conducts the purified air from the filter/blower to
the head piece. The filter/blower system consists of a
replaceable HEPA (high efficiency particulate air) filter
cartridge unit powered by rechargable batteries and a blower
motor. Particles of gr--ater than 0.3 microns in diameter are
filtered w'th 99.9977, accuracy. Positive pressure is maintained
'in order to prevent entry of unfiltered air into the suit.
Ask.—
The filter system weighs 5.5 pounds; the blower motor weighs
0.43 pounds. A manual blower system is provided in the event
of power system failure.
It is anticipated that the BIG could be sold commercially
for approximately $1000 to $2000, depending on production
quantities and possible design variables.
2.2 Nature of Use
Biological Isolation Garment
The scope of this study was limited to medical applications
in which a patient is subject to a high degree of risk of
infection from the normal hospital environment, either as a
result of a disease itself or treatment of a disease. For
these applications, the Biological Iso'ation Garment must be
used in conjunction with a statio:.ary sterile environment such
as a laminar air flow patient isolator. The B1G then becomes
an extension of the controlled environment, allowing patients
to leave the confines of the isolation unit while still being
t^-w '.ntained in a controlled environment, Egress from the
isolator may be required for treatment in other parts of the
hospital (i.e., x-ray, radiotherapy). In addition, the BIG
would enable a patient to more closely interact with
visitors or simply break the monotony of isolation, factors
which may be very important for patients psychologically less
able to tolerate an extended period of isolation.
In summary, the BIG i n its present design is an adjunct
to a patient isolation system and as such, has no clinical
application other than as an extension of a protected environ-
ment. Thus, in order to determine the commercial potential
of the BIG, nature and extent of use of patient isolators must
first be assessed.
I
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Patien t Isolators
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The term v atient isolator, a facility in which a patient
is protected from the hospital environment, generally refers
to a controlled environment in which the air supply is received
through HEPA filters. Most have laminar air flow, where the
entire body of air within the confined space moves with
uniform velocity over parallel flow lines. The basic protec-
tive capability of this concep. is the fact that airborne
organisms cannot migrate against an air flow. The incoming
air flow is filtered by means of HEPA filte-s, ensuring
protection against organisms of greater that 0.3 micron in
diameter. The patient care area is maintained at a slightly
higher pressure; any air leakage is thus outward rather than
inward	 A nearly sterile environment is maintained by:
- Thorough cleaning of units before they are
reoccupied
- Patients must undergo extensive decontamination
procedures prior to isolation
- All equipment and material entering the room
must be sterilized.
- Procedure or method to allow medical staff access
to patient without contaminating the environment
Lamtnar flow rooms have been Used for rr .J.ent care for
over six years; operating room facilities 1 	 been in existence
for nearly 10 years. Laminar flow and ultra-clean facilities
are also used in industry; however, these applications are
beyond the scope of the study. Both portable and stationary
laminar air flow rooms are commercially available; designs
are available for use in existing single hospital rooms and
wards. Most are single patient units, althougli multiple bed
units are available.
3
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Laminar flow facilities range in price from $5,000 to
$30,000 depending on ancillary equipment, size, configuracion,
etc. The significant cost of the isolators is, however,
operating rather than acquisition coat. In a 1972 study conducted
b y Arthur D. Little, Inc, for the National Cancer Institute,
it was estimated that the operating cost for one research
unit studied was approximately $800 per patient day . In a
four-bed lamina: flow unit, costs were estimated at $200 to
$300 additional per patient day over the cost of conventional
hospital rooms.
Typical clin-Lcal applications for patient isolators
include:
- Chemotherapy/leukemia treatment
- Transplantation
- Burns
- Radiation injury
- Immune disease
- Intensive care units
- Respiratory disease
- Pediatric isolation
The clinical objective in reverse isolation is to protect
hospital patients who are highly vulnerable to infection from
the environment. This is a very severe problem for certain patients:
for examp le, infectious comp lications are responsible for nearly
70% of all deaths in acute leukemia. This susceptibility may
be caused by a number of factors, for example:
- Administration of immuno-suppressive drugs as
in organ or mar-.ow transplants or for patients
with acute '_euJKemia
- Impair+nent of natural immunity and/or bone marrow
function- as in intensive chemotherapy and radiation
injury
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- Consequence of condition itself, as combined
immcne deficiency and aplastic anemia
- Result of severe trauma, as with burns or
extensive surgery.
Where impairment of natural immunitv is induced as part of a
treatment protocol as in 2hemotherapy or transplantation,
evidence indicates that reverse isolation may enable the
physician to administer more therapeutic agents while still
not significantly increasing risk of infection, a usual
complicating factor of such treatment.
Although the reverse isolation facilities for patient
care have been in hospital use for a significant period of
time, many authorities still consider them to be at the
expe rie mental or research stage. Their benefit and efficacy
is still a point of controversy. Isolation in a bacteria
free environment may be a significant contribution to the
health care needs of certain hospital patients or it may provide
little or no substantial benefit. For example, the conclusion
of a recent study of this issue concluded that while laminar
air flow facilities are a promising research tool and the
evidence is clear that their use can reduce morbidity and
mortality, the ultimate utility of isolation rooms in
enhancing long term survival for a significant number of
patients has not been established.
Surgical or operating room units have received more wide-
spread acceptance; use is especially prevalent for orthopedic
surgical procedures such as total hip replacement. It is
estimated that there are approximately 1500 operating room
units currently in use.
* F. Drazen, A. Levine, "Laminar Air flow Rooms", Hospitals
Vol. 48, Jan. 1, 1974.
2. 3 Market Need/Acceptance
In general, the medical community tends to be slow in
adonting new items of technology unless the advantages and
benefits are very clear" demonstrated. The benefits of
reverse isolation apparently have not been p:-oven beyond doubt,
and therefore the probability of widespread adoption in the
near term is uncertain.
The benefit; and advantages of the BIG, a complementary
device must thus be clearly demonstrated as well. If reverse
isolation becomes a common treatment method, clinical accep-
t£, nce and use of the BIG will. then depend upon factors such
as the following:
- Adv..ntage over current practice
- Benefits in terms of expanded treatment possibilities
- Acceptance of garment's reliability
- Patient attitudes towards wearing the garment
- Anticipated frequency of use
- Price and operating/maintenance cost
3. SIZE O1' THE MARKET
3.1 Patient Isolators
In order to determine the commercial potential of the
Biological Isolation Garment, the current and future extent of
use of patient care laminar flow rooms will be assessed.
Based on available data, we estimate that approximately 160 to
200 laminar flow patient isolators have been purchased for
domestic use to date. Slip_htly less than half have been
purchased by U.S. Cancer Centers; the remainder are in general
and other government hospitals. Of the seventeen cancer centers,
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twelve are reported to have patient isolator units, an average
of over five units per center. However, M.D. Anderson
(University of Texas), one of the original cancer centers,
reportedly has 26 units; if this is discounted, the average
per cancer center drops to approximately three to four.
Hospitals other than c- l scer centers have an average of two
units each. Overall, our research indicates that nearly half
of the total units are used primarily for chemotherapy/acute
leukemia treatment.
The adoption of patient isolators has been slow. Moreover,
purchases by general and other hospitals appears to be
diminishing: only 1/3 of the total were purchased after 1972.
U.S. cancer centers, however, have increased their acquisition
of units over the last three years.
The market for patient isolators is dominated by three
suppliers, who account for over 75% of sales. Several firms
who supplied units in the past have gone out of business or
have eliminated or de-emphasized hospital sales. The market
has been difficult to develop and expand because of factors
such as:
- Large research expense associated with manufacturing
- High cost of sales to a geographically disbursed market
- Long sales lead time
- Medical community tend to regard isolation units as a
research item
3.2 Biological Isolation Garment
The maximum size of the current market- for the Biological
Isolation Garment for medical use is li^.ii-ted to the patient
isolation facilities currently in place (assuming that they are
utilized). One garment would be required per patient unit,
since the garment can be sterilized between patients.
7
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The current market for the Biolog'cal Isolation Garment
is thus 1.60-200 units, the number of patient isolators in
place (the majority are one patient facilities). At an
estimated sales price of $1000 t . $2000 per garment, the
maximum current market is approximately $160,000 to $400,000.
Since the BIG has been successfully tested in clinical use,
it is likely that adoption of the garment may be relatively
rapid, at minimum an estimated one garment per hospital, or
approximately 60 units within one to two years after commer-
cialization.
Future sales potential could expand considerably if the
patient isolation concept is accepted as standard practice
by the medical community. It is virtually impossible to
predict when this will occur.
4. COMPETITIVE ENVIRONMENT AND CHANNELS OF DISTRIBUTION
4.1 C:ompetitiv%.^ Environment
During the course of our research, we identified no
commercially available products to provide a mobile sterile
environment for patients confined to isolator units. If it is
necessary to remove the patient from the isolator, (for example,
for treatment in another part of the hospital) current practice
is to dress the patient in a sterile surgical gown and mask
in order to minimize risk of infection. Alternatively, the
problem is often circui;ivented by bringing portable equipment
which has been decontaminated into the isolator.
4.2 Channels of Distribution
The most appropriate channel of distribution for the BIG
would be direct sales contact either through a company sales
fore or through distributors with established hospital
contacts.	 Direct sales contact is commonly used for patient
8
isolators, and since the items are complementary, greatest
sales q uccess would likely be achieved if sold together.
5. COMMERCIAL POTENTIAL
At
5.1 Market Penetration
Approximately one to two years would be required for a
new company to develop the necessary sales and manufacturing
capabilities to produce and commercialize the Biological
Isolation Garment. This time could possibly be reduced,
howevever, by a company adding the BIG to an existing line
of patient isolators or hospital products.
Assuming that more widespread adoption of patient
isolators occurs, expected sales of the BIG would also depend
upon factors such as the following:
- Magnitude of sales effort
- Price at which the BIG can be sold
- Operation and maintenance cost
- Patient acceptance of BIG
- Development of non-medical applications
5.2 Price/ Performance Impact
The sales price --)f the Biological Isolation Garment is
difficult to specify at this time, but it is anticipated
that it could be sold for approximately $1000 to $2000 depending
on design and production variables. Price/performance impact
must thus be assessed in terms of the incremental benefit of
the BIG to treatment of certain hospital patients. Several
manufacturers of patient isolators felt that the market is
very cost sensitive, and price would be very important,
especially when reverse isolation units are in use less than
y
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half of the time.
5.3 Anticipated Market Barriers_
The primary factors which we foresee as potentially
affecting market acceptance of the Biological Isolation Garment
(assuming acceptance of patient isolators) are:
- Present practices may be considered satisfactory
- Patient rejection of bulky su!_t
The primary means overcoming barriers to acceptance is
demonstration and wide dissemination of clinical test results
and anticipated benefits of the garment. The medical community
must first accept the fact that the BIG offers significantly
greater protection than present practice end that it would
be a useful addition to patient care. Similarly, any objections
wb,,.tr, 1 patient may have to the appearance and comfort
vi the garment would be minimized or eliminated if it is
demonstrated that risk of infection is reduced or possible
activities expanded.
5.4 Interested Manufacturers
Seven firms have expressed interest in performing a
detailed evaluation of the Biological Isolation Garment to
explore manufacturing and sales possibilities. Four firms are
manufacturers of patient isolators; the remainder manufacture
and distribute other hospital supplies and equipment. The
following is a list of interested companies, along with the
name of the primary contact and relevant products.
10
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Company
Angelica Uniform Company
St. Louis, Mo.
Envi rco Corp.
Albuquerque, NM.
Environmental General
Corp.
.,'Alexandria, Va.
Lzi-Med Environmental
Systems, Inc.
Minneapolis, Minn.
G.D. :,earle
Skokie, Illinois
Stackhouse Associates
Manhatten Beach, Ca.
Weber 'Technical Products,
In.
Lunenburg, uass.
Contact	 Product
Hal Pohle	 "BAR-BAC" Fabric
Pirector of Hospital Mktg.
Lou Sanders	 Laminar flow
General Sales Manager 	 isolation rooms
and -urgical
isolators
Gabriel Danch	 Laminar flow
President	 patient 2nviron-
ment
Paul D. Pederson, jr.	 Laminar flow
Vice President	 patient isolation
system
Wellman Hoff	 Di,;;rsified
Corporate Research	 health care
products
Wyman Stackhouse
	
"Bio-vak" surgical
President	 mask system
Al Dettenreider	 Patient and
Manager, Medical Products	 surgical isola-
tors
5.5 Patent Status
A patent on the Biological Isolation Garment, author
t-y F.R. Spross, has been issued to NASA. Patent number
3,51.b,404 describing "contamination proof wearing apparel" was
i.scu':d in 1970.
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6.1 Conclusions
The following conclusions are made on the basis of our
market study:
• The BIG is potentially a useful and beneficial addition
to the health care requirements or certain hospital
patients
• There are no competitive products available; current
practice includes using a surgical gown and mask
outside the isolator or circumventing the problem by
bringing decontaminated portable equipment into the
isolator.
• The BIG has been successfully tested in clinical use
by the National. Cancer Institute
• The BIG must be used in conjunction with a patient
isolator, aE a means of extending the controlled
environment beyond the isolation room
• The commercial potential of the BIG depends on the rate
of adoption and use of patient isolators
• Adoption and use of patient isolators has been slow
and there is still some degree of doubt as to their
benefit; however, acceptance of innovations by the
medical community is typically slow unless there is a
very clear demonstration of benefits.
• There are approximately 160 to 200 patient isolation
units in use, representing the maximum current market
for the BIG.
• This limited sales potential must be weighed against
anticipated benefits to certain patients
6.2 Recommendations
• The BIG would have the greatest likelihood of commercial
success if s,.Id in conjunction wi t^ patient isolators
or other hospital supplies, for t:.- :mellowing reasons:
- Sales channels already developed
12
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- R&D expense may be luwer
- Limited market to support profitability
• NASA. should consider the possibilit-y of granting an
exclusive license on the technology as an incentive
for a firm to commit the re;uired manufacturing and
sales development funds.
• A;ditional prototype units should be developed for
further clinical evaluation and wide dissemination of
te9t results.
• Industrial and other medical applications for the
garment should be explored, for example:
- Use in sterile manufacturing processes, such as
pharmaceuticals anO electronics
- Use as a protective garment for certain industrial
accidents
- Modification of design for use by sterile operating
room personnel
• Promote and possibl y support the involvement of interested
manufacturers in any necessary product refinement and
commercial development effor `.
• Wide dissemination of clinical test results is vital to
attain favorable exposure in the medical community.
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